Melissa Cambron
Melissa Cambron has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Valenzuela Espinoza
Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium
1 shared publication Anke Maertens
Icometrix, R&D, Leuven, Belgium
1 shared publication- Ann De Smedt
STIMULUS Research Group, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
1 shared publication Annemie Ribbens
Icometrix, R&D, Leuven, Belgium
1 shared publication- Diana Maria Sima
Icometrix, Leuven, Belgium
1 shared publication Dirk Smeets
Icometrix, R&D, Leuven, Belgium
1 shared publication
Latest Publications
- 13 November 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (1) , 177-185
Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients
We assessed the humoral and cellular immune responses after two booster mRNA vaccine administrations [BNT162b2 (Pfizer-BioNTech vaccine)] in cohorts of immunocompromised patients (n = 199) and healthy controls (HC) (n = 54). All patients living with HIV (PLWH) and chronic kidney disease (CKD) patients and almost all (98.2%) of the primary immunodeficiency (PID) patients had measurable antibodies 3 and 6 months after administration of the third and fourth vaccine dose, comparable to the HCs. In contrast, only 53.3% and 83.3% of the multiple sclerosis (MS) and rheumatologic patients, respectively, developed a humoral immune response. Cellular immune response was observed in all PLWH after administration of four vaccine doses. In addition, cellular immune response was positive in 89.6%, 97.8%, 73.3% and 96.9% of the PID, MS, rheumatologic and CKD patients, respectively. Unlike the other groups, only the MS patients had a significantly higher cellular immune response compared to the HC group. Administration of additional vaccine doses results in retained or increased humoral and cellular immune response in patients with acquired or inherited immune disorders.
- 13 November 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (1) , 177-185
Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients
We assessed the humoral and cellular immune responses after two booster mRNA vaccine administrations [BNT162b2 (Pfizer-BioNTech vaccine)] in cohorts of immunocompromised patients (n = 199) and healthy controls (HC) (n = 54). All patients living with HIV (PLWH) and chronic kidney disease (CKD) patients and almost all (98.2%) of the primary immunodeficiency (PID) patients had measurable antibodies 3 and 6 months after administration of the third and fourth vaccine dose, comparable to the HCs. In contrast, only 53.3% and 83.3% of the multiple sclerosis (MS) and rheumatologic patients, respectively, developed a humoral immune response. Cellular immune response was observed in all PLWH after administration of four vaccine doses. In addition, cellular immune response was positive in 89.6%, 97.8%, 73.3% and 96.9% of the PID, MS, rheumatologic and CKD patients, respectively. Unlike the other groups, only the MS patients had a significantly higher cellular immune response compared to the HC group. Administration of additional vaccine doses results in retained or increased humoral and cellular immune response in patients with acquired or inherited immune disorders.
- Open Access
- 30 March 2016
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 5 (1) , e9
Opinions and Beliefs About Telemedicine for Emergency Treatment During Ambulance Transportation and for Chronic Care at Home
Interactive Journal of Medical Research
- 30 March 2016
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 5 (1) , e9
Open AccessOpinions and Beliefs About Telemedicine for Emergency Treatment During Ambulance Transportation and for Chronic Care at Home
Interactive Journal of Medical Research
- Open Access
- 1 January 2015
- Published by Elsevier in NeuroImage: Clinical
- Vol. 8, 367-375
Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images
- 1 January 2015
- Published by Elsevier in NeuroImage: Clinical
- Vol. 8, 367-375
Open AccessAutomatic segmentation and volumetry of multiple sclerosis brain lesions from MR images